PMID: 9633898Jun 20, 1998Paper

Butyrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells

British Journal of Haematology
V SantiniP Rossi Ferrini

Abstract

The rapid degradation and subsequent lack of efficacy of n-butyric acid in vivo has been improved by the synthesis of monosaccharide stable pro-drugs of butyric acid. We studied the effects of D1 (O-n-butanoyl-2,3-O-isopropylidene-alpha-D-mannofuranoside), G1 (1-O-n-butanoyl-D,L-xylitol), and F1 (1-O-n-butanoyl 2,3-O-isopropylidene-D,L-xylitol) on the maturation and proliferation of AML cell lines HL 60 and FLG 29.1 and of purified blast cells from 10 cases of de novo acute myeloid leukaemia (AML). AML cell maturation was measured by surface antigen expression, morphology and cytochemistry. Toxicology in mice was also evaluated (DL50 1000 mg/kg). In HL 60 cells G1 and D1 increased the expression of CD15 and CD11a (presenting 62% of promyelo-metamyelocytes), and in 7/10 cases of primary AMLs that of CD11a, CD11b, CD15, and myeloperoxidase. D1, G1 and F1 induced a dose-dependent inhibition of tritiated thymidine uptake. Apoptosis (evaluated by flow cytometry and agarose gel electrophoresis) was induced in AML blasts by D1 and F1 (79% and 94% respectively for HL 60 cells) and, with less effect, by G1 (27%). The persistence of maturative and apoptotic activity in these new pro-drugs of butyric acid, hydrolysed only inside the tumou...Continue Reading

References

May 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·S J CollinsR C Gallo
Oct 15, 1976·Biochemical Pharmacology·F H Schneider
Jun 19, 1992·International Journal of Cancer. Journal International Du Cancer·P PouillartC Chany
May 30, 1991·International Journal of Cancer. Journal International Du Cancer·P PlanchonD Brouty-Boyé
Mar 1, 1990·Clinical and Experimental Immunology·S J MartinT G Cotter
Jan 1, 1988·Leukemia Research·M SalemB Löwenberg
Sep 1, 1987·European Journal of Cancer & Clinical Oncology·A A MillerC G Schmidt
Oct 29, 1987·Biochemical and Biophysical Research Communications·S P PerrineD V Faller
Aug 31, 1993·Biochemical and Biophysical Research Communications·C CalabresseD Belpomme
Apr 25, 1996·Biochemical and Biophysical Research Communications·S T Chang, B Y Yung
Dec 10, 1998·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·P PouillartP Villa

❮ Previous
Next ❯

Citations

Apr 7, 2005·Digestive Diseases and Sciences·Arkadiusz OrchelTadeusz Wilczok
Nov 17, 2001·Current Opinion in Pharmacology·E Garattini, M Terao
Sep 30, 1998·British Journal of Haematology·V Santini, P R Ferrini
Nov 9, 2001·Leukemia & Lymphoma·V SantiniP Rossi Ferrini
Sep 23, 2003·Expert Opinion on Therapeutic Targets·Karl J TronstadØystein Bruserud

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.